Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Reprieve Cardiovascular Launches With $42M

2024-02-20
MILFORD, MA, Reprieve Cardiovascular today announced it has raised a total of $42 million in series A financing.
Reprieve Cardiovascular, a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing. The total round was co-led by Lightstone Ventures and Sante Ventures and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures. The funding will advance the Company's clinical and development programs, including the ongoing FASTR trial and its upcoming pivotal trial.

Reprieve Cardiovascular is developing innovative and groundbreaking therapies that aim to improve the lives of more than 25 million heart failure patients around the world. Reprieve is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients. In 2022, Reprieve initiated the FASTR Trial (pilot study) to compare decongestive therapy administered by the Reprieve Decongestion Management System to Optimal Diuretic Therapy in the treatment of patients diagnosed with acute decompensated heart failure.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors